

SIOPE Course in Paediatric Oncology
2-Day Virtual Kick-Off Meeting 2021

26-27 March 2021

Programme



Friday 26 March		
08:45 – 9:00	Welcome and introduction Andishe Attarbaschi (AT), Reineke Schoot (NL) and Pamela Kearns (UK)	
	Solid tumor track – GROUP A	Liquid tumor track – GROUP B
	Chair and moderators: Hans Merks (NL) & Reineke Schoot (NL)	Main chair & moderator: Andishe Attarbaschi (AT)
09:00 – 9:45	Integrated modern biology in diagnosis Rita Alaggio (IT)	Initial emergencies in leukemia Valentino Conter (IT)
09:45 – 10:00	Clinical case presentation Hans Merks (NL)	Clinical case presentation Andishe Attarbaschi (AT)
10:00 – 11:00	Preparation, 4 working groups: <ol style="list-style-type: none"> 1. Imaging: differential diagnosis of this case, plan for obtaining tissue/diagnosis Kieran McHugh (UK) 2. Pathology results: how to integrate information on imaging, histology and biology? Rita Alaggio (IT) <p>Discuss possibilities for systemic treatment</p> <ol style="list-style-type: none"> 3. Chemotherapy Hans Merks (NL) 4. Crizotinib & Larotrectinib Veronique Minard (FR) 	Preparation, 3 working groups: <ol style="list-style-type: none"> 1. Diagnostics, protocol, risk group Andishe Attarbaschi (AT) 2. Response assessment Martin Schrappe (DE) 3. Toxicity Kjeld Schmiegelow (DK)
11:00 – 11:15	Coffee break with possibility for virtual meeting	
	Solid tumor track – GROUP A	Liquid tumor track – GROUP B
11:15 – 12:15	Cancer board H. Merks, V. Minard, R. Alaggio, K. McHugh	Leukemia board V. Conter, M. Schrappe, K. Schmiegelow, A. Attarbaschi
12:15 – 13:00	Lunch break with possibility for virtual meeting	
	Solid tumor track – GROUP A	Liquid tumor track – GROUP B
13:00 – 13:30	Access to new drugs and reimbursement issues Gilles Vassal (FR)	Immunotherapy in ALL Michel Zwaan (NL)

13:30 – 14:15	Preparation of 2 nd Cancer board, patient from morning session progressed: <ul style="list-style-type: none"> 1. Advocate for phase 1/2 trial Gilles Vassal (FR) 2. Infectious management Thomas Lehrnbecher (DE) 3. TKI resistance Veronique Minard (FR) 4. Shared decision making, communication tips Carina Schneider (AT) 	Preparation of 2 nd Cancer board, patient from morning session progressed: <ul style="list-style-type: none"> 1. Best supportive care Lillian Sung (CA) 2. Relapse and its management Carmelo Rizzari (IT) 1. CAR-T-cell therapy Francesco Ceppi (CH)
14:15 – 15:00	Cancer board G. Vassal, T. Lehrnbecher, V. Minard, C. Schneider, H. Merks, K. McHugh	Leukemia board L. Sung, C. Rizzari, A. Attarbaschi, M. Schrappe, F. Ceppi
15:00 – 15:20	Coffee break with possibility for virtual meeting	
15:20– 16:00	Quiz: repetition learning points day 1 Roelof van Ewijk (NL)	Quiz: repetition learning points day 1 Jelena Lazic, RS

Saturday 27 March		
08:45 – 9:00	Welcome and introduction Andishe Attarbaschi (AT), Reineke Schoot (NL) and Pamela Kearns (UK)	
	Solid tumor track – GROUP B	Liquid tumor track – GROUP A
	Chair and moderators: Hans Merks (NL) & Reineke Schoot (NL)	Main chair & moderator: Andishe Attarbaschi (AT)
09:00 – 9:45	Integrated modern biology in diagnosis Rita Alaggio (IT)	Initial emergencies in leukemia Valentino Conter (IT)
09:45 – 10:00	Clinical case presentation Hans Merks (NL)	Clinical case presentation Andishe Attarbaschi (AT)
10:00 – 11:00	Preparation, 4 working groups: <ol style="list-style-type: none"> 1. Imaging: differential diagnosis of this case, plan for obtaining tissue/diagnosis Kieran McHugh (UK) 2. Pathology results: how to integrate information on imaging, histology and biology? Rita Alaggio (IT) <p>Discuss possibilities for systemic treatment</p> <ol style="list-style-type: none"> 3. Chemotherapy Hans Merks (NL) 4. Crizotinib & Larotrectinib Veronique Minard (FR) 	Preparation, 3 working groups: <ol style="list-style-type: none"> 1. Diagnostics, protocol, risk group Andishe Attarbaschi (AT) 2. Response assessment Andishe Attarbaschi (AT) 3. Toxicity Kjeld Schmiegelow (DK)
11:00 – 11:15	Coffee break with possibility for virtual meeting	
	Solid tumor track – GROUP B	Liquid tumor track – GROUP A
11:15 – 12:15	Cancer board H. Merks, V. Minard, R. Alaggio, K. McHugh	Leukemia board V. Conter, K. Schmiegelow, A. Attarbaschi
12:15 – 13:00	Lunch break with possibility for virtual meeting	
	Solid tumor track – GROUP B	Liquid tumor track – GROUP A
13:00 – 13:30	Access to new drugs and reimbursement issues Gilles Vassal (FR)	Immunotherapy in ALL Michel Zwaan (NL)

13:30 – 14:15	Preparation of 2 nd Cancer board, patient from morning session progressed: <ol style="list-style-type: none"> 1. Advocate for phase 1/2 trial Gilles Vassal (FR) 2. Infectious management Thomas Lehrnbecher (DE) 3. TKI resistance Veronique Minard (FR) 4. Shared decision making, communication tips Carina Schneider (AT) 	Preparation of 2 nd Cancer board, patient from morning session progressed: <ol style="list-style-type: none"> 1. Best supportive care Lillian Sung (CA) 2. Relapse and its management Carmelo Rizzari (IT) 3. CAR-T-cell therapy Francesco Ceppi (CH)
14:15 – 15:00	Cancer board G. Vassal, T. Lehrnbecher, V. Minard, C. Schneider, H. Merks, K. McHugh	Leukemia board L. Sung, C. Rizzari, A. Attarbaschi, F. Ceppi
15:00 – 15:20	Coffee break with possibility for virtual meeting	
15:20– 16:00	Explanation of complex trials, process of informed consent Pam Kearns (UK)	
16:00 – 16:30	Quiz: repetition learning points day 2 Roelof van Ewijk (NL) & Jelena Lazic, RS	
16:30 – 17:00	Adjourn and final remarks with faculty and participants, group picture	